Patents Examined by Sheridan Swope
  • Patent number: 11319569
    Abstract: The disclosure provides an active peptide with an anti-lipid oxidation function and a preparation method and application thereof and belongs to the technical field of plant-derived biologically active peptides. In the disclosure, oil processing by-products, namely oil crops after oil extraction, are used as the raw materials, and the raw materials are subjected to the steps of protein extraction, infrared pretreatment, proteolysis, freeze-drying, lipophilic part extraction, vacuum concentration and drying to prepare an anti-lipid oxidation peptide having the functional characteristics of scavenging DPPH free radicals, chelating metal ions, inhibiting lipid peroxidation, prolonging vegetable oil oxidation induction time, improving emulsion stability and the like.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 3, 2022
    Assignee: Jiangnan University
    Inventors: Yuanfa Liu, Zhaojun Zheng, Jiaxin Li, Yongjiang Xu, Yin Chen
  • Patent number: 11268074
    Abstract: Disclosed is a modified microorganism producing putrescine or ornithine, and a method for producing putrescine or ornithine using the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: March 8, 2022
    Assignee: CJ Cheiljedang Corporation
    Inventors: Su Jin Park, Young Lyeol Yang, Hye Won Um, Hong Xian Li, Kyoung Min Lee, Baek Seok Lee, Hyo Hyoung Lee, Hee Kyoung Jung
  • Patent number: 11261471
    Abstract: Disclosed herein are methods and compositions for making vault particles in yeast hosts and yeast vaults produced therefrom.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: March 1, 2022
    Assignees: The Regents of the University of California, Vault Pharma Inc.
    Inventors: Leonard H. Rome, Shaily Mahendra, Meng Wang, Valerie A. Kickhoefer, Oliver Karl Foellmer
  • Patent number: 11248219
    Abstract: Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: February 15, 2022
    Assignees: Ipsen Bioinnovation Limited, Allergan, Inc.
    Inventors: Peter James, Keith Foster, John Chaddock, Roger Aoki, Lance Steward, Joseph Francis
  • Patent number: 11242511
    Abstract: The disclosure relates to a cytoplasmic protein complex comprising: (a) a first recombinant fusion protein comprising a kinase, fused to a first interaction polypeptide; and (b) a second recombinant fusion protein comprising a domain comprising a reporter phosphorylation site, whereby the domain is fused to a second interaction polypeptide. The disclosure relates further to a method to detect compound-compound-interaction using the cytoplasmic protein complex, and to cells comprising such cytoplasmic protein complex.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: February 8, 2022
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Samuel Lievens
  • Patent number: 11241025
    Abstract: Methods for enhancing phytase thermal stability by fusing binding elements to target phytases are provided. Engineered phytases that include binding elements fused to target phytases to cause cyclization of the engineered phytases and enhance thermal stability of the target phytases are described. Engineered nucleic acids encoding engineered phytases and hosts engineered to express engineered nucleic acids are also provided. Methods for incorporating engineered phytases in animal feed and animal feed including the same are described.
    Type: Grant
    Filed: May 6, 2020
    Date of Patent: February 8, 2022
    Assignee: AGRIVIDA, INC.
    Inventors: R. Michael Raab, Gabor Lazar, Binzhang Shen
  • Patent number: 11234446
    Abstract: A liquid or dried granulated milk clotting aspartic protease enzyme composition and process for isolating a milk clotting aspartic protease enzyme of interest.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 1, 2022
    Assignee: CHR. HANSEN A/S
    Inventors: Martin Lund, Jonas Jacobsen, Johannes Maarten Van Den Brink
  • Patent number: 11235037
    Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 1, 2022
    Assignee: Polaris Group
    Inventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
  • Patent number: 11229686
    Abstract: A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: January 25, 2022
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Rajendra Pradhan, Xiang Gao
  • Patent number: 11214782
    Abstract: The disclosure relates, in general, to Glycogen Storage Disease Type VI and, in particular, to a method of treating Glycogen Storage Disease Type VI and to compounds and compositions suitable for use in such a method.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: January 4, 2022
    Assignee: Duke University
    Inventors: Yuan-Tsong Chen, Priya Kishnani, Baodong Sun
  • Patent number: 11214785
    Abstract: Disclosed herein are modified strains for reducing degradation of recombinantly expressed products secreted from a host organism and methods of using the modified strains. In some embodiments, to attenuate a protease activity in Pichia pastoris, the genes encoding enzymes the degrade proteases are inactivated or mutated to reduce or eliminate activity. In preferred strains, the protease activity of proteases encoded by PAS_chr4_0584 (YPS1-1) and PAS_chr3_1157 (YPS1-2) (e.g., polypeptides comprising SEQ ID NO: 66 and 67) is attenuated.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: January 4, 2022
    Assignee: Bolt Threads, Inc.
    Inventors: Matthew Scott Gamboa, Joshua Tyler Kittleson
  • Patent number: 11213574
    Abstract: Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 4, 2022
    Assignee: Thrombolytic Science, LLC
    Inventor: Victor Gurewich
  • Patent number: 11203621
    Abstract: The present invention provides a tool which exhibits excellent properties in the quantification of autophagy activity. A unimolecular FRET probe of the present invention includes an acceptor consisting of a fluorescent protein to be enzymatically degraded inside a lysosome or a vacuole; and a donor having an amino acid sequence having a sequence identity of 95% or more with respect to an amino acid sequence represented by SEQ ID NO: 1.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 21, 2021
    Assignee: RIKEN
    Inventors: Atsushi Miyawaki, Hiroyuki Katayama
  • Patent number: 11193117
    Abstract: The present invention is directed generally to cell-targeted cytotoxic constructs comprising a targeting polypeptide, a linking polypeptide and a cytotoxic polypeptide. Preferably, (a) the targeting polypeptide is a R-spondin1 (RSPO1), R-spondin2 (RSPO2) or yoked chorionic gonadotropin (YCG), the linking polypeptide comprises LPXT (SEQ ID NO: 56) or NPXT (SEQ ID NO: 60) as well as others, where X is any amino acid, the linking polypeptide being positioned between the targeting ligand and (c) the cytotoxic moiety is an auristatin or a truncated serine protease, the serine protease having an IIGG (SEQ ID NO: 91), IVGG (SEQ ID NO: 92) or ILGG (SEQ ID NO: 93) at its N-terminus. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer).
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 7, 2021
    Assignee: Research Development Foundation
    Inventors: Xinjian Lin, Xiying Shang, Stephen B. Howell
  • Patent number: 11180740
    Abstract: Reaction compositions are disclosed herein comprising at least water, alpha-glucose-1-phosphate (alpha-G1P), an acceptor molecule, and a beta-1,3-glucan phosphorylase enzyme. These reactions can synthesize oligosaccharides and polysaccharides with beta-1,3 glycosidic linkages. Further disclosed are methods of isolating beta-1,3-glucan.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: November 23, 2021
    Assignee: DANISCO US INC
    Inventors: Zheyong Yu, Slavko Kralj, Natnael Behabtu, Zhenghong Zhang, Laurie A Howe
  • Patent number: 11180747
    Abstract: The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: November 23, 2021
    Assignee: Codexis, Inc.
    Inventors: Goutami Banerjee, Jie Yang, Xiyun Zhang, Erika M. Milczek, Melissa Ann Mayo, Stephan Jenne
  • Patent number: 11162949
    Abstract: A method for rapidly and highly sensitively measuring endotoxin relies on an endotoxin-measuring agent, which includes a factor C derived from Tachypleus tridentatus that does not have His-tag sequence at the C-terminus, a factor B of a horseshoe crab, and a proclotting enzyme of a horseshoe crab. Each of these proteins can be a recombinant protein obtainable by being expressed using a stably expressing cell line of an insect cell as a host.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 2, 2021
    Assignee: Seikagaku Corporation
    Inventors: Hikaru Mizumura, Maki Aizawa, Toshio Oda
  • Patent number: 11135275
    Abstract: Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 5, 2021
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Ida Hilden, Bernd Peschke, Jens Breinholt, Mikael Kofod-Hansen
  • Patent number: 11104867
    Abstract: In a dishwashing liquid, the cleaning performance, in particular on bleachable stains such as, for example, tea stains, is to be improved. This succeeds using a dishwashing liquid which comprises a hydrogen peroxide source, a bleaching catalyst and a protease that, in native electrophoresis on a polyacrylamide gel, has a migration distance that is longer than the migration distance of the protease as per SEQ ID NO. 1.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 31, 2021
    Inventors: Nina Mussmann, Thomas Eiting, Thorsten Bastigkeit, Konstantin Benda, Hendrik Hellmuth, Thomas Weber
  • Patent number: 11078509
    Abstract: The present invention relates to mutants of a parent Trichoderma strain, comprising a polynucleotide encoding a polypeptide and one or more (several) genes selected from the group consisting of a first subtilisin-like serine protease gene, a first aspartic protease gene, a trypsin-like serine protease gene, a second subtilisin-like serine protease gene, and a second aspartic protease gene, wherein the one or more (several) genes are modified rendering the mutant strain deficient in the production of one or more (several) enzymes selected from the group consisting of a first subtilisin-like serine protease, a first aspartic protease, a trypsin-like serine protease, a second subtilisin-like serine protease, and a second aspartic protease, respectively, compared to the parent Trichoderma strain when cultivated under identical conditions. The present invention also relates to methods of producing a polypeptide in such mutants and methods for producing such mutants.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 3, 2021
    Assignee: Novozymes, Inc.
    Inventors: Suchindra Maiyuran, Abigail Jang, Kimberly Brown, Sandra Merino, Jeffrey Shasky, Eric Abbate